Investor & Media Presentation
Metall Zug AG - Welcome
March 24, 2025
Martin Wipfli, Chairman of the Board
Matthias Rey, CEO
Urs Scherrer, CFO
METALL ZUG GROUP
Content
- Group Financial Report
- Business Units
- Medical Devices
- Technologycluster & Infrastructure
- Investments & Corporate
- Conclusions
- Sustainability
Investor & Media Presentation - March 24, 2025 | 2 |
METALL ZUG GROUP
What we have planned and what we achieved 2024
Others
- Increase sales with a focus on US and Asian markets
- Review the implementation of strategic initiatives
- R&D push: Further development of microscopy (analogue and digital), digitalization of devices and product updates
- Successful closing of joint venture transaction with Miele, start combined enterprise and define target picture
- Keep market share during initial combination phase between Belimed and Steelco
- Further increase the share of recurring revenues (service, consumables)
- Approval of land development plan for project Pi and obtaining building permit for Crea Tower I
- Conclusion of design study for refActory
- Opening of "KunstCluster" in Zug (art workshop)
- Strengthen business excellence and internal efficiency of Gehrig Group
- Successfully launch new dishwasher line "Ariane"
Investor & Media Presentation - March 24, 2025 | 3 |
Group Financial Report FY 2024
Metall Zug Group
Investor & Media Presentation - March 24, 2025
Medical Devices | Technologycluster & | Investments & Corporate |
Infrastructure |
METALL ZUG GROUP
Income Statement
Metall Zug Group
2024 | in % | 2023 | in % Comment |
(in CHF million)
Net sales | 283.4 | 100.0 | 494.7 | 100.0 |
Cost of Goods and Services sold | -192.5 | -67.9 | -343.7 | -69.5 |
Gross Profit | 90.9 | 32.1 | 151.0 | 30.5 |
Marketing and sales expenses | -41.2 | -14.5 | -56.7 | -11.5 |
Research and development expenses | -33.2 | -11.7 | -41.0 | -8.3 |
Administation expenses | -40.3 | -14.2 | -53.8 | -10.9 |
Other operating income | 80.4 | 28.4 | 13.5 | 2.7 |
Other operating expenses | -1.7 | -0.6 | 0.1 | 0.0 |
Trading operating result | 54.9 | 19.4 | 13.1 | 2.7 |
Result from strategic investments | 3.1 | 1.1 | 17.0 | 3.4 |
Operating result (EBIT) | 58.0 | 20.4 | 30.1 | 6.1 |
Financial Result | -0.3 | -0.1 | 0.9 | 0.2 |
Result before taxes | 57.6 | 20.3 | 31.0 | 6.3 |
Taxes | -4.8 | -1.7 | -5.0 | -1.0 |
Net result | 52.8 | 18.6 | 26.0 | 5.3 |
FY 2024 includes gain of CHF 66.6 million from JV SteelcoBelimed
FY 2024: GHG-fund contribution of CHF 1.4 million (2023: CHF 2.0 million) FY 2023: Includes CHF 2.1 million income from release of provision from disposal of UK pension plan
Investor & Media Presentation - March 24, 2025 | 5 |
METALL ZUG GROUP
Strategic Investments
Metall Zug Group
Komax Group | V-ZUG Group SteelcoBelimed | Total |
(in CHF million) | ||||||||
2024 attributable result | -4.1 | 5.7 | 1.5 | 3.1 | ||||
- thereof current year pro rata net result | -0.8 | 6.5 | 1.5 | 7.2 | ||||
- thereof adjustment previous year's actual result | -3.3 | -0.8 | 0.0 | -4.1 | ||||
Book value (proportional equity) | 89.2 | 147.3 | 58.6 | 295.1 | ||||
Market value (share price as of December 31) | 147.6 | 95.6 | n/a | n/a | ||||
2023 attributable result | 13.9 | 3.1 | 17.0 | |||||
- thereof current year pro rata net result | 14.3 | 4.3 | 18.6 | |||||
- thereof adjustment previous year's actual result | -0.4 | -1.2 | -1.6 | |||||
Book value (proportional equity) | 107.7 | 141.3 | 249.0 | |||||
Market value (share price as of December 31) | 257.3 | 126.2 | n/a |
Investor & Media Presentation - March 24, 2025 | 6 |
Net Sales FY 24
by Business Unit
by region
17%
(24%)
24%
(38%)
Medical Devices
Infection Control
Investments & Corporate
Investor & Media Presentation - March 24, 2025
59%
(38%)
15%
(15%)
35%
(35%)
Switzerland
Europe w/o Switzerland
Americas
Asia/Pacific/Others
17%
(17%)
33%
(33%)
(Previous year's values in brackets)
7
METALL ZUG GROUP
Net Sales Analysis
in CHF million
600.0
550.0
500.0
450.0
400.0
350.0
300.0
250.0
200.0
494.7 -166.4
-3.9 | -14.0 | -8.8 | 283.4 | |
-3.1 | ||||
-19.4 | ||||
4.4 | ||||
494.7 | -166.4 | -3.9 | -14.0 | -19.4 | -3.1 | -8.8 | 4.4 | 283.4 |
Net sales | Deconsolidation | FX | Investments & | Technologycluster | Infection Control | Medical Devices | Consolidation | Net sales |
FY 2023 | Belimed Groups | Corporate | & Infrastructure | FY 2024 |
Investor & Media Presentation - March 24, 2025 | 8 |
METALL ZUG GROUP
Operating Result (EBIT) Analysis
in CHF million
140.0
120.0
100.0
80.0
60.0
40.0
20.0
0.0
66.6-21.7
-2.3
-0.5 | -14.1 | 58.0 |
-0.1 |
30.1
30.1 | 66.6 | -21.7 | -2.3 | -0.5 | -14.1 | -0.1 | 58.0 |
EBIT | Gain SteelcoBelimed | Investments & | Technologycluster & | Infection Control | Medical Devices | IC-Elimination | EBIT |
FY 2023 restated | Corporate | Infrastructure | FY 2024 | ||||
(excl. Gain | |||||||
SteelcoBelimed) |
Investor & Media Presentation - March 24, 2025 | 9 |
METALL ZUG GROUP
Balance Sheet
Metall Zug Group
12/31/2024 | in % 12/31/2023 | in % Comment |
(in CHF million)
Cash and cash equivalents / securities | 17.2 | 2.7 | 29.8 | 4.3 | ||||
Other current assets | 112.3 | 17.7 | 206.9 | 30.0 | ||||
Current assets | 129.5 | 20.5 | 236.7 | 34.4 | ||||
Tangible assets | 168.7 | 26.6 | 169.6 | 24.6 | ||||
Financial assets | 333.0 | 52.6 | 279.2 | 40.5 |
2024 includes strategic investments in V-ZUG, Komax and SteelcoBelimed (equity value) of CHF 295 million (2023: CHF 249 million).
Intangible assets | 1.7 | 0.3 | 3.4 | 0.5 | ||||
Fixed assets | 503.4 | 79.5 | 452.1 | 65.6 | ||||
Total assets | 633.0 | 100.0 | 688.9 | 100.0 | ||||
Current & long-term financial liabilities | 82.8 | 13.1 | 36.6 | 5.3 | ||||
Other liabilities | 63.7 | 10.1 | 132.2 | 19.2 | ||||
Total liabilities | 146.5 | 23.2 | 168.8 | 24.5 | ||||
Shareholders' equity | 486.4 | 76.8 | 520.0 | 75.5 | ||||
Total liabilities and shareholders' equity | 633.0 | 100.0 | 688.9 | 100.0 | ||||
Net debt position | -65.6 | -10.4 | -6.8 | -1.0 |
Investor & Media Presentation - March 24, 2025 | 10 |